Table 3.
Frequency of hospitalizations due to bone complications
| Outcome | At-risk perioda | EU5b N = 813 |
France N = 146 |
Germany N = 175 |
Italy N = 173 |
Spain N = 141 |
UK N = 173 |
|---|---|---|---|---|---|---|---|
| Hospitalizations due to bone complications by at-risk period, n (%)c | |||||||
| Any bone complication | Overall | 119 (15) | 20 (14) | 33 (19) | 22 (13) | 20 (14) | 24 (14) |
| Period 1 | 73 (9) | 11 (8) | 21 (12) | 14 (8) | 14 (10) | 14 (8) | |
| Period 2 | 29 (4) | 4 (3) | 10 (6) | 4 (2) | 3 (2) | 7 (4) | |
| Period 3 | 41 (5) | 9 (6) | 11 (6) | 6 (4) | 7 (5) | 7 (4) | |
| Hospitalizations due to bone complications by type of bone complication and at-risk period, n (%)d | |||||||
| PF | Overall | 79 (66) | 11 (55) | 26 (79) | 13 (59) | 16 (80) | 15 (63) |
| Period 1 | 54 (74) | 6 (55) | 19 (91) | 8 (57) | 13 (93) | 11 (79) | |
| Period 2 | 11 (37) | 1 (25) | 3 (30) | 2 (50) | 0 | 4 (57) | |
| Period 3 | 24 (58) | 5 (56) | 8 (72) | 3 (50) | 5 (71) | 3 (43) | |
| SCC | Overall | 20 (17) | 4 (20) | 4 (12) | 4 (18) | 2 (10) | 5 (21) |
| Period 1 | 15 (21) | 4 (36) | 2 (10) | 2 (14) | 2 (14) | 4 (29) | |
| Period 2 | 2 (8) | 0 | 0 | 0 | 0 | 2 (29) | |
| Period 3 | 7 (18) | 1 (11) | 2 (18) | 2 (33) | 0 | 2 (29) | |
| RB | Overall | 46 (39) | 8 (40) | 14 (42) | 4 (18) | 5 (25) | 13 (54) |
| Period 1 | 21 (28) | 5 (46) | 4 (19) | 3 (21) | 0 | 6 (43) | |
| Period 2 | 16 (55) | 2 (50) | 5 (50) | 1 (25) | 3 (100) | 5 (71) | |
| Period 3 | 17 (41) | 4 (44) | 5 (46) | 0 | 3 (43) | 4 (57) | |
| SB | Overall | 36 (30) | 5 (25) | 12 (36) | 11 (50) | 2 (10) | 5 (21) |
| Period 1 | 20 (28) | 1 (9) | 8 (38) | 7 (50) | 1 (7) | 4 (29) | |
| Period 2 | 10 (35) | 1 (25) | 4 (40) | 2 (50) | 1 (33) | 2 (29) | |
| Period 3 | 9 (21) | 3 (33) | 1 (9) | 3 (50) | 1 (14) | 0 | |
EU5 five European countries (France, Germany, Italy, Spain and the UK), PF pathologic fracture, RB radiation to bone, SB surgery to bone, SCC spinal cord compression, UK United Kingdom
aOverall: from multiple myeloma diagnosis to disease progression following first-line treatment; period 1: before initiation of induction therapy; period 2: during active first-line therapy; period 3: after treatment discontinuation
bAggregated EU5 data have been weighted based on the multiple myeloma incidence in each country so base sizes for individual countries may not equal the EU5 total
cExpressed as a percentage of the total number of patients
dExpressed as a percentage of the number of patients who were hospitalized owing to a bone complication